MX2013001327A - Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion. - Google Patents
Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion.Info
- Publication number
- MX2013001327A MX2013001327A MX2013001327A MX2013001327A MX2013001327A MX 2013001327 A MX2013001327 A MX 2013001327A MX 2013001327 A MX2013001327 A MX 2013001327A MX 2013001327 A MX2013001327 A MX 2013001327A MX 2013001327 A MX2013001327 A MX 2013001327A
- Authority
- MX
- Mexico
- Prior art keywords
- hmgbl
- protein
- hmgb1
- antibody
- fecal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 230000002550 fecal effect Effects 0.000 title claims abstract description 29
- 238000001514 detection method Methods 0.000 title claims description 10
- 230000004968 inflammatory condition Effects 0.000 title abstract description 3
- 239000000090 biomarker Substances 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000055207 HMGB1 Human genes 0.000 claims abstract description 33
- 108700010013 HMGB1 Proteins 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 29
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims abstract description 23
- 101150021904 HMGB1 gene Proteins 0.000 claims abstract description 23
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 22
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 22
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 20
- 238000004458 analytical method Methods 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 13
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 230000008506 pathogenesis Effects 0.000 claims abstract description 5
- 238000012286 ELISA Assay Methods 0.000 claims abstract 3
- 238000003119 immunoblot Methods 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000009010 Bradford assay Methods 0.000 claims description 2
- 239000002033 PVDF binder Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000011536 extraction buffer Substances 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000000605 extraction Methods 0.000 claims 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 210000003608 fece Anatomy 0.000 abstract description 10
- 238000001262 western blot Methods 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 201000010099 disease Diseases 0.000 description 37
- 230000004054 inflammatory process Effects 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 230000000968 intestinal effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 5
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 229940117360 ethyl pyruvate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000442A IT1406051B1 (it) | 2010-08-05 | 2010-08-05 | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| PCT/IT2011/000276 WO2012017466A1 (en) | 2010-08-05 | 2011-08-01 | Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013001327A true MX2013001327A (es) | 2013-03-08 |
Family
ID=43739596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001327A MX2013001327A (es) | 2010-08-05 | 2011-08-01 | Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130137123A1 (enExample) |
| EP (1) | EP2601525A1 (enExample) |
| JP (1) | JP2013534313A (enExample) |
| CN (1) | CN103069276A (enExample) |
| AU (1) | AU2011287193B2 (enExample) |
| BR (1) | BR112013002145A2 (enExample) |
| CA (1) | CA2807107C (enExample) |
| CL (1) | CL2013000223A1 (enExample) |
| EA (1) | EA201390197A1 (enExample) |
| IL (1) | IL223845A (enExample) |
| IT (1) | IT1406051B1 (enExample) |
| MX (1) | MX2013001327A (enExample) |
| PE (1) | PE20131062A1 (enExample) |
| WO (1) | WO2012017466A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| PT2968443T (pt) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Análogos de hepcidina e seus usos |
| SG10201810321PA (en) | 2014-05-16 | 2018-12-28 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| ES2977537T3 (es) | 2014-07-17 | 2024-08-26 | Protagonist Therapeutics Inc | Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018089693A2 (en) * | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| DK3622082T3 (da) | 2017-05-12 | 2023-06-12 | Evonik Operations Gmbh | Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok |
| IT201700083044A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| IT201700083055A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3092472A1 (en) * | 2018-03-02 | 2019-09-06 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| CN109030817A (zh) * | 2018-07-04 | 2018-12-18 | 长沙都正医学检验有限责任公司 | Hmgb1检测试剂盒及其制备方法 |
| ES2938227T3 (es) | 2018-12-14 | 2023-04-05 | Evonik Operations Gmbh | Método in vitro de detección de disbiosis intestinal aviar |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| CN115279782A (zh) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途 |
| IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| IL302996B2 (en) | 2020-11-20 | 2025-04-01 | Janssen Pharmaceutica Nv | Compositions of interleukin-23 receptor peptide inhibitors |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577671A1 (en) * | 1996-07-17 | 2005-09-21 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| EP1601969A2 (en) * | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
| WO2007001422A2 (en) * | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| WO2008075788A1 (ja) * | 2006-12-20 | 2008-06-26 | Shino-Test Corporation | ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬 |
| EP2185936A4 (en) * | 2007-08-02 | 2010-08-04 | Iss Immune System Stimulation | DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE |
| US7833721B2 (en) * | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
-
2010
- 2010-08-05 IT ITRM2010A000442A patent/IT1406051B1/it active
-
2011
- 2011-08-01 JP JP2013522346A patent/JP2013534313A/ja active Pending
- 2011-08-01 CN CN2011800327624A patent/CN103069276A/zh active Pending
- 2011-08-01 AU AU2011287193A patent/AU2011287193B2/en not_active Ceased
- 2011-08-01 EA EA201390197A patent/EA201390197A1/ru unknown
- 2011-08-01 WO PCT/IT2011/000276 patent/WO2012017466A1/en not_active Ceased
- 2011-08-01 US US13/814,294 patent/US20130137123A1/en not_active Abandoned
- 2011-08-01 BR BR112013002145A patent/BR112013002145A2/pt not_active IP Right Cessation
- 2011-08-01 EP EP11754539.2A patent/EP2601525A1/en not_active Withdrawn
- 2011-08-01 PE PE2013000131A patent/PE20131062A1/es not_active Application Discontinuation
- 2011-08-01 MX MX2013001327A patent/MX2013001327A/es unknown
- 2011-08-01 CA CA2807107A patent/CA2807107C/en not_active Expired - Fee Related
-
2012
- 2012-12-24 IL IL223845A patent/IL223845A/en active IP Right Grant
-
2013
- 2013-01-23 CL CL2013000223A patent/CL2013000223A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20131062A1 (es) | 2013-10-16 |
| IT1406051B1 (it) | 2014-02-06 |
| IL223845A (en) | 2016-06-30 |
| US20130137123A1 (en) | 2013-05-30 |
| CA2807107A1 (en) | 2012-02-09 |
| WO2012017466A8 (en) | 2013-07-11 |
| CN103069276A (zh) | 2013-04-24 |
| BR112013002145A2 (pt) | 2016-05-24 |
| AU2011287193B2 (en) | 2015-08-13 |
| EP2601525A1 (en) | 2013-06-12 |
| CA2807107C (en) | 2017-01-03 |
| JP2013534313A (ja) | 2013-09-02 |
| ITRM20100442A1 (it) | 2012-02-06 |
| EA201390197A1 (ru) | 2013-06-28 |
| AU2011287193A1 (en) | 2013-06-13 |
| CL2013000223A1 (es) | 2014-03-28 |
| WO2012017466A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2807107C (en) | Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof | |
| Sakurai et al. | Positioning and usefulness of biomarkers in inflammatory bowel disease | |
| Roda et al. | Crohn’s disease | |
| Kaiser et al. | Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome | |
| Leach et al. | Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease | |
| Carroccio et al. | Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome | |
| KR20100063052A (ko) | 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법 | |
| Jessen et al. | Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab | |
| Wędrychowicz et al. | Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis | |
| CN110488025A (zh) | 一种化学发光定量检测粪便钙卫蛋白及其检测方法和其在肠道健康检测的用途 | |
| El-Salhy | Recent advances in the diagnosis of irritable bowel syndrome | |
| Klimczak et al. | The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity | |
| Al | Biochemical significance of cystatin-C and high-sensitive CRP in patients with acute coronary syndrome; any clinical correlation with diagnosis and ejection fraction | |
| Pham et al. | Subclinical intestinal inflammation in siblings of children with Crohn’s disease | |
| Giulia et al. | Crohn’s disease (Primer) | |
| Toğrol et al. | The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study | |
| Ghosh et al. | P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib | |
| Waluga | Biomarkers of irritable bowel syndrome | |
| CN114270191B (zh) | 炎症性肠病诊断方法、诊断探针和诊断试剂盒 | |
| KR20130136964A (ko) | 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트 | |
| US20230074127A1 (en) | Test and in vitro diagnosis of irritable bowel syndrome | |
| WO2020221942A1 (en) | A method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease | |
| Saruta | Positioning and Usefulness of Biomarkers in Inflammatory Bowel | |
| TWI614501B (zh) | ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途 | |
| Şimşek et al. | Fecal S100A12 as a Biomarker in Behcet’s Disease |